MOLN / Molecular Partners AG - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 •MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025 •IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano Med •Appointed Martin Steegmaier, Ph.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557

As filed with the Securities and Exchange Commission on June 25, 2025

As filed with the Securities and Exchange Commission on June 25, 2025 Registration No.

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Molecular Partners AG (“Molecular Partners,” the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered

Exhibit Filing fee table CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, CHF 0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 44755770

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway •Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025 •Cash reach now anticipated to extend into 2028 Zurich-Schlieren, Switzerland and Concord, Mass.

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements (Nos. 333-272974 and 333-280491) on Form S-8 and in the Registration Statement (No. 333-265960) on Form F-3 of our report dated March 6, 2025, which was filed on Form 20-F, with respect to the consolidated financial statements of Molecular Partners AG. /

Molecular Partners Reports Financial Results and Highlights from Q1 2025

Molecular Partners Reports Financial Results and Highlights from Q1 2025 •Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027 •IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programs •Data from dosing cohort 8 in Phase 1/2a trial of MP0533 demonstrate increased rates and depth of responses; study protocol amendment now approved, and dosing cohort 9 enrollment initiated, additional data expected in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass.

Condensed consolidated interim statement of financial position as of March 31, 2025 December 31, 2024 in CHF thousands Note Assets Property, plant and equipment 4,120 4,198 Intangible assets 24 49 Total non-current assets 4,144 4,247 Short-term time

Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of March 31, 2025 December 31, 2024 in CHF thousands Note Assets Property, plant and equipment 4,120 4,198 Intangible assets 24 49 Total non-current assets 4,144 4,247 Short-term time deposits 49,536 85,565 Other current assets 2,069 2,525 Trade and other receivables 3,977 2,317 Cash and cash equivalents 81,371 63,874 Total current assets 136,953 154,281 Total assets 141,097 158,528 Shareholders' equity and liabilities Share capital 5.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557700

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 4475577

[Signature page follows]

April 22, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Molecular Partners AG Registration Statement on Form F-3 Filed April 11, 2025 File No. 333-286488 Acceleration Request Requested Date: April 24, 2025 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule

As filed with the Securities and Exchange Commission on April 11, 2025

As filed with the Securities and Exchange Commission on April 11, 2025 Registration No.

Calculation of Filing Fee Tables Form F-3 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value CHF 0.

Consent of Independent Registered Public Accounting Firm

Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-265960) on Form F-3 of our report dated March 6, 2025, with respect to the consolidated financial statements of Molecular Partners AG. /s/ KPMG AG Zurich, Switzerland March 6, 2025

- 2 -

Exhibit 1.1 Statuten von Molecular Partners AG vom Januar 9, 2025 Articles of Incorporation of Molecular Partners Ltd as of January 9, 20251 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - - 3 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration of the C

CERTIFICATION

Exhibit 13.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Patrick Amstutz, Chief Executive Officer of Molecular Partners AG (the “Company”), and Robert Hendriks, SVP Finance of the Company, each hereby certifies th

DEVELOPMENT AND OPTION AGREEMENT

Exhibit 4.8 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DEVELOPMENT AND OPTION AGREEMENT This Development and Option Agreement (this “Agreement”) is made and entered into effective as of January 11, 2025 (the “Effective Date”) by a

PSU Award Agreement 2025

Molecular Partners AG: Performance Share Plan 2025 - Employees Exhibit 4.20 Molecular Partners AG Performance Share Plan 2025 Employees Molecular Partners AG: Performance Share Plan 2025 - Employees Table of Contents 1. Performance Share Plan 2025 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of PSUs 4 6. No

2

Exhibit 4.7 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. October 21, 2024 RE: Research and Development Collaboration and Option Agreement (“Agreement”) dated 5 January 2024 between Orano Med, a French simplified joint-stock company,

At a Glance • Pioneering a new class of custom-built protein drugs known as DARPin therapeutics • Advancing a diverse portfolio of unique DARPin product candidates that are designed to offer solutions for serious diseases other therapies cannot readi

At a Glance • Pioneering a new class of custom-built protein drugs known as DARPin therapeutics • Advancing a diverse portfolio of unique DARPin product candidates that are designed to offer solutions for serious diseases other therapies cannot readily address • Partnering with leading pharmaceutical companies to unlock new DARPin therapeutic capabilities to advance our portfolio and the drug class Company Profile Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

EXHIBIT 99.1 Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 DLL3 targeting Radio-DARPin MP0712 to enter first-in-human study in 2025, pending regulatory clearance Strategic partnership with Orano Med on Radio-DARPins now expanded to ten programs MP0533 Phase 1/2a clinical data show improved response rate and depth in ongoing cohort, additional dosing optim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

CERTIFICATION

Exhibit 12.2 CERTIFICATION I, Robert Hendriks, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Partners AG (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 4475577

CERTIFICATION

Exhibit 12.1 CERTIFICATION I, Patrick Amstutz, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Partners AG (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislea

SECURITIES TRADING POLICY

Exhibit 11.1 SECURITIES TRADING POLICY TABLE OF CONTENTS 1 PURPOSE 1 2 SCOPE 2 3 REFERENCES 2 3.1 Regulatory Guidelines 2 3.2 Governing Documents 2 4 DEFINITIONS AND ABBREVIATIONS 3 4.1 Definitions 3 4.2 Abbreviations 3 5 PROCEDURE 4 5.1 Relevant Securities 4 5.2 Insider Information 4 5.3 General Restrictions 5 5.3.1 Restrictions based on Insider Information 5 5.3.2 Restrictions outside Trading Wi

RSU Award Agreement 2025

Molecular Partners AG: Restricted Share Plan 2025 Exhibit 4.29 Molecular Partners AG Restricted Share Plan 2025 Molecular Partners AG: Restricted Share Plan 2025 2 | 9 Table of Contents 1. Restricted Share Plan 2025 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of RSUs 4 6. No Securities 5 7. No Transfer 5 8.

PSU Award Agreement 2025

Molecular Partners AG: Performance Share Plan 2025 – Management Board Exhibit 4.21 Molecular Partners AG Performance Share Plan 2025 Management Board Molecular Partners AG: Performance Share Plan 2025 – Management Board 2 | 10 Table of Contents 1. Performance Share Plan 2025 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

EXHIBIT 99.1 Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025 Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano Med Orano Med partnership on

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

EXHIBIT 99.1 Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to ten Expanded partnership highlights the parties’ emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med’s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025 RDT strategic a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557700 (A

Condensed consolidated interim statement of financial position as of September 30, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 4,598 5,681 Intangible assets 82 212 Total non-current assets 4,680 5,893 Short-term

Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of September 30, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 4,598 5,681 Intangible assets 82 212 Total non-current assets 4,680 5,893 Short-term time deposits 77,866 119,580 Other current assets 2,595 3,617 Trade and other receivables 3,318 1,953 Cash and cash equivalents 65,752 67,309 Total current assets 149,531 192,459 Total assets 154,211 198,352 Shareholders' equity and liabilities Share capital 5.

MOLN / Molecular Partners AG - Depositary Receipt (Common Stock) / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Molecular Partners AG (Name of Issuer) Common Shares, CHF 0.10 nominal value per share (Title of Class of Securities) 60853G106 (CUSIP Number) JAMES KR

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Exhibit 99.1 Molecular Partners Announces Pricing of $20 Million Underwritten Offering ZURICH-SCHLIEREN, Switzerland, and CONCORD, Mass., Oct. 25, 2024 - Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company

Statuten von Molecular Partners AG vom October 25, 2024 Articles of Incorporation of Molecular Partners Ltd as of October 25, 20241 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail.

Exhibit 3.1 Execution Version Statuten von Molecular Partners AG vom October 25, 2024 Articles of Incorporation of Molecular Partners Ltd as of October 25, 20241 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Du

MOLECULAR PARTNERS AG 3,642,988 American Depositary Shares, representing 3,642,988 Ordinary Shares Underwriting Agreement

Exhibit 1.1 Execution Version MOLECULAR PARTNERS AG 3,642,988 American Depositary Shares, representing 3,642,988 Ordinary Shares Underwriting Agreement October 24, 2024 Leerink Partners LLC TD Securities (USA) LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 c/o TD Securities (USA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557700 (A

3,642,988 American Depositary Shares Representing 3,642,988 Ordinary Shares $5.49 per American Depositary Share

Filed Pursuant to Rule 424(b)(5) Registration File No. 333-265960 PROSPECTUS SUPPLEMENT (To Prospectus Dated July 12, 2022) 3,642,988 American Depositary Shares Representing 3,642,988 Ordinary Shares $5.49 per American Depositary Share We are offering 3,642,988 of our American Depositary Shares, or ADSs. Each ADS represents one ordinary share with a nominal value of CHF 0.10 per share. The ADSs ma

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

EXHIBIT 99.1 Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics Under the revised agreement, both companies will co-develop four Radio-DARPin programs; each company will have the right to commercialize two programs (previously one each) Molecular Partners will hold commercial rights to the second nominated Radio-DARPin Candidate, in addition t

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

EXHIBIT 99.2 Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision attributes for alpha radiation thera

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Condensed consolidated interim statement of financial position as of June 30, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 4,891 5,681 Intangible assets 122 212 Total non-current assets 5,013 5,893 Short-term time

Exhibit 99.3 Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of June 30, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 4,891 5,681 Intangible assets 122 212 Total non-current assets 5,013 5,893 Short-term time deposits 93,440 119,580 Other current assets 3,108 3,617 Trade and other

Molecular Partners AG

Exhibit 99.2 Business Update Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first half-year of 2024. “In the first half of 2024, we made substantial progress with ou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557700 (Ad

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Exhibit 99.1 Molecular Partners Reports H1 2024 Corporate Highlights and Financials First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 Strategic collaboration agreement signed with Orano Med to co-develop 212Pb-based RDT candidates for multiple oncology targets, including MP0712 MP0533 phase 1 dose

- 2 -

Statuten von Molecular Partners AG vom April 17, 2024 Articles of Incorporation of Molecular Partners Ltd as of April 17, 20241 1 This is a translation of the original German version.

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, CHF 0.

As filed with the Securities and Exchange Commission on June 26, 2024

As filed with the Securities and Exchange Commission on June 26, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executiv

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 •Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators •Preclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effects •MP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass.

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 •Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment •Favorable and manageable safety profile observed at all tested dose levels •Weekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmacodynamics •Data support further clinical evaluation of MP0317 in combination settings ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass.

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 •MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano Med •Positive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety profile •First-in-human study in planning with initial data expected in 2025 •RDT platform expanding with portfolio of additional targets under evaluation ZURICH-SCHLIEREN, Switzerland, CONCORD, Mass.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executiv

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

EXHIBIT 99.1 Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano Med Positive tumor to kidney ratio and biodistribution, favorable antitumor activity and safety pro

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

EXHIBIT 99.1 Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favorable and manageable safety profile observed at all tested dose levels Weekly and three-weekly dosi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executiv

Condensed consolidated interim statement of financial position as of March 31, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 5,254 5,681 Intangible assets 165 212 Total non-current assets 5,419 5,893 Short-term tim

Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of March 31, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 5,254 5,681 Intangible assets 165 212 Total non-current assets 5,419 5,893 Short-term time deposits 105,788 119,580 Other current assets 2,874 3,617 Trade and other receivables 3,179 1,953 Cash and cash equivalents 68,345 67,309 Total current assets 180,186 192,459 Total assets 185,605 198,352 Shareholders' equity and liabilities Share capital 5.

1

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program •MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being prepared •Radio-DARPin Therapy (RDT): Lead DLL3 candidate adva

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557700 (Add

1

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program •MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being prepared •Radio-DARPin Therapy (RDT): Lead DLL3 candidate adva

Condensed consolidated interim statement of financial position as of March 31, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 5,254 5,681 Intangible assets 165 212 Total non-current assets 5,419 5,893 Short-term tim

Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of March 31, 2024 December 31, 2023 in CHF thousands Note Assets Property, plant and equipment 5,254 5,681 Intangible assets 165 212 Total non-current assets 5,419 5,893 Short-term time deposits 105,788 119,580 Other current assets 2,874 3,617 Trade and other receivables 3,179 1,953 Cash and cash equivalents 68,345 67,309 Total current assets 180,186 192,459 Total assets 185,605 198,352 Shareholders' equity and liabilities Share capital 5.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557700 (Addre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

Molecular Partners Publishes Invitation to Annual General Meeting 2024

EXHIBIT 99.1 Molecular Partners Publishes Invitation to Annual General Meeting 2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) - Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2024.

RESEARCH AND DEVELOPMENT COLLABORATION AND OPTION AGREEMENT

Exhibit 4.6 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. RESEARCH AND DEVELOPMENT COLLABORATION AND OPTION AGREEMENT This Research and Development Collaboration and Option Agreement (this “Agreement”) is made and entered into effe

RSU Award Agreement 2024

Molecular Partners AG: Restricted Share Plan 2024 Exhibit 4.24 Molecular Partners AG Restricted Share Plan 2024 1 Molecular Partners AG: Restricted Share Plan 2024 Table of Contents Restricted Share Plan 2024 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of RSUs 4 6. No Securities 5 7. No Transfer 5 8. Vestin

Molecular Partners AG Incentive Compensation Recoupment Policy

Exhibit 97.1 Molecular Partners AG Incentive Compensation Recoupment Policy 1.Introduction The Nomination and Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) and the Board of Molecular Partners AG, a stock corporation (Aktiengesellschaft) organized under the laws of Switzerland (the “Company”), have determined that it is in the best interests of the Co

CERTIFICATION*

Exhibit 12.2 CERTIFICATION* I, Robert Hendriks, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Partners AG (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misle

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC

CERTIFICATION*

Exhibit 12.1 CERTIFICATION* I, Patrick Amstutz, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Partners AG (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misle

- 2 -

Statuten von Molecular Partners AG vom 16. Januar 2024 Articles of Incorporation of Molecular Partners Ltd as of January 16, 20241 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - - 3 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration of the Company Art

CERTIFICATION

Exhibit 13.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Patrick Amstutz, Chief Executive Officer of Molecular Partners AG (the “Company”), and Robert Hendriks, SVP Finance of the Company, each hereby certifies th

PSU Award Agreement 2024

Molecular Partners AG: Performance Share Plan 2024 - Employees Exhibit 4.16 Molecular Partners AG Performance Share Plan 2024 Employees 1 Molecular Partners AG: Performance Share Plan 2024 - Employees Table of Contents Performance Share Plan 2024 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of PSUs 4 6. No S

Consent of Independent Registered Public Accounting Firm

Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-265960) on Form F-3 of our report dated March 14, 2024, with respect to the consolidated financial statements of Molecular Partners AG. /s/ KPMG Zurich, Switzerland March 14, 2024

PSU Award Agreement 2024

Molecular Partners AG: Performance Share Plan 2024 – Management Board Molecular Partners AG Performance Share Plan 2024 Management Board 1 Molecular Partners AG: Performance Share Plan 2024 – Management Board Table of Contents Performance Share Plan 2024 3 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

EXHIBIT 99.1 Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024 Progress of Radio-DARPin Therapy (RDT) platform: Improved tumor to kidney uptake ratio enables expansion of RDT pipeline; first data on DLL3 as lead candidate; to

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

EXHIBIT 99.1 Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies Collaboration leverages lead-based (212Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive payloads Co-Development agreement covers multiple oncology targets, including DLL3 Companies anticipate first-in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

EXHIBIT 99.1 Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously rep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

MOLN / Molecular Partners AG - ADR / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Molecular Partners AG (Name of Issuer) Common Shares, CHF 0.10 nominal value per share (Title of Class of Securities) 60853G106 (CUSIP Number) JAMES KRA

JOINT FILING AGREEMENT

EX-99.1 2 ex991to13d07422moln11202023.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D dated November 20, 2023 (including amendments thereto) with respect to the Common Shares, CHF 0.

MOLN / Molecular Partners AG - ADR / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 4 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga407422moln11072023.htm AMENDMENT NO. 4 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Molecular Partners AG (Name of Issuer) Common Shares, CHF 0.10 nom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

EXHIBIT 99.1 Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to date Emer

Condensed consolidated interim statement of financial position as of September 30, 2023 December 31, 2022 in CHF thousands Note Assets Property, plant and equipment 5,919 7,235 Intangible assets 266 271 Total non-current assets 6,185 7,506 Short-term

Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of September 30, 2023 December 31, 2022 in CHF thousands Note Assets Property, plant and equipment 5,919 7,235 Intangible assets 266 271 Total non-current assets 6,185 7,506 Short-term time deposits 138,225 161,198 Other current assets 3,523 4,589 Trade and other receivables 1,786 1,019 Cash and cash equivalents 68,399 87,946 Total current assets 211,933 254,752 Total assets 218,118 262,258 Shareholders' equity and liabilities Share capital 5.

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio

Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio •MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2023 •MP0533 Phase 1/2a recruitment in r/r AML patients proceeding as planned

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2023 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 44755

Molecular Partners Reports H1 2023 Corporate Highlights and Financials

Molecular Partners Reports H1 2023 Corporate Highlights and Financials Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Zürich-Schlieren Switzerland Telephone: +41 447557

Condensed consolidated interim statement of financial position as of June 30, 2023 December 31, 2022 in CHF thousands Note Assets Property, plant and equipment 6,357 7,235 Intangible assets 277 271 Total non-current assets 6,634 7,506 Short-term time

Exhibit 99.3 Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of June 30, 2023 December 31, 2022 in CHF thousands Note Assets Property, plant and equipment 6,357 7,235 Intangible assets 277 271 Total non-current assets 6,634 7,506 Short-term time deposits 154,952 161,198 Other current assets 4,154 4,589 Trade and othe

Business Update

Exhibit 99.2 Business Update Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the first half-year of 2023. “Throughout the first half of the year, our team has w

- 2 -

Statuten von Molecular Partners AG vom 4. April 2023 Articles of Incorporation of Molecular Partners Ltd as of April 4, 20231 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration of the Company Artikel 1 Arti

As filed with the Securities and Exchange Commission on June 28, 2023

As filed with the Securities and Exchange Commission on June 28, 2023 Registration No.

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, CHF 0.

Condensed consolidated interim financial statements (unaudited)

Exhibit 99.1 Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of March 31, 2023 December 31, 2022 in CHF thousands Note Assets Property, plant and equipment 6,768 7,235 Intangible assets 287 271 Total non-current assets 7,055 7,506 Short-term time deposits 158,442 161,198 Other current assets 3,363 4,589 Trade and oth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executive

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

EXHIBIT 99.1 Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy MP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort (Q3W, 10mg/kg) now enrolling; clinical update at ASCO Rad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

Molecular Partners Publishes Invitation to Annual General Meeting 2023

EXHIBIT 99.1 Molecular Partners Publishes Invitation to Annual General Meeting 2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 13, 2023 (GLOBE NEWSWIRE) - Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2023.

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 2.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Molecular Partners AG (“Molecular Partners,” the “Company,” “we,” “us,” and “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the

Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022

EXHIBIT 99.1 Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022 Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) Presented preclinical data supporting the unique design and mechanism of MP0533 at the

Management Board PSU Award Agreement 2023

Exhibit 4.14 Molecular Partners AG: Performance Share Plan 2023 – Management Board Molecular Partners AG Performance Share Plan 2023 Management Board Molecular Partners AG: Performance Share Plan 2023 – Management Board Table of Contents Performance Share Plan 2023 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Gran

RSU Award Agreement 2023

Exhibit 4.20 Molecular Partners AG: Restricted Share Plan 2023 Molecular Partners AG Restricted Share Plan 2023 Molecular Partners AG: Restricted Share Plan 2023 Table of Contents Restricted Share Plan 2023 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of RSUs 4 6. No Securities 4 7. No Transfer 4 8. Vesting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC

- 2 -

Exhibit 1.1 Statuten von Molecular Partners AG vom 19. Januar 2023 Articles of Incorporation of Molecular Partners Ltd as of January 19, 20231 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration of the Compa

Management Board PSU Award Agreement 2021

Molecular Partners AG: Performance Share Plan 2021 – Management Board Exhibit 4.10 Molecular Partners AG Performance Share Plan 2021 Management Board 1 Molecular Partners AG: Performance Share Plan 2021 – Management Board Table of Contents Performance Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Gr

RSU Award Agreement 2022

Molecular Partners AG: Restricted Share Plan 2022 Exhibit 4.19 Molecular Partners AG Restricted Share Plan 2022 1 Molecular Partners AG: Restricted Share Plan 2022 Table of Contents Restricted Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of RSUs 4 6. No Securities 4 7. No Transfer 4 8. Vestin

_____________________________________________________________________ LICENSE AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG MOLECULAR PARTNERS AG

Exhibit 4.4 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG AND MOLECULAR PARTNERS AG 264813180 v3 Table of Contents 1. DEFINITIONS AND INTERPRETATION 3 2. LICENSE 17 3. GOVERNANCE 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

Management Board PSU Award Agreement 2022

Molecular Partners AG: Performance Share Plan 2022 – Management Board Exhibit 4.12 Molecular Partners AG Performance Share Plan 2022 Management Board 1 Molecular Partners AG: Performance Share Plan 2022 – Management Board Table of Contents Performance Share Plan 2022 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Gr

Employee PSU Award Agreement 2023

Exhibit 4.13 Molecular Partners AG: Performance Share Plan 2023 - Employees Molecular Partners AG Performance Share Plan 2023 Employees Molecular Partners AG: Performance Share Plan 2023 - Employees Table of Contents Performance Share Plan 2023 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of PSUs 4 6. No Sec

Employee PSU Award Agreement 2022

Molecular Partners AG: Performance Share Plan 2022 - Employees Exhibit 4.11 Molecular Partners AG Performance Share Plan 2022 Employees 1 Molecular Partners AG: Performance Share Plan 2022 - Employees Table of Contents Performance Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of PSUs 4 6. No S

CERTIFICATION

Exhibit 13.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Patrick Amstutz, Chief Executive Officer of Molecular Partners AG (the “Company”), and Robert Hendriks, VP Finance of the Company, each hereby certifies tha

ORGANIZATIONAL RULES MOLECULAR PARTNERS AG Approved by the Board of Directors October 6, 2014 (as amended as of May 12, 2017, September 20, 2017, February 5, 2019, April 29, 2020 and March 14, 2022) TABLE OF CONTENTS

Exhibit 1.2 ORGANIZATIONAL RULES OF MOLECULAR PARTNERS AG Approved by the Board of Directors October 6, 2014 (as amended as of May 12, 2017, September 20, 2017, February 5, 2019, April 29, 2020 and March 14, 2022) TABLE OF CONTENTS I. GENERAL PROVISIONS 3 1. BASIS 3 2. SCOPE 3 II. BOARD OF DIRECTORS 3 3. ORGANIZATION 3 4. FUNCTION AND POWERS 4 5. DUTIES 4 6. DELEGATION AND SIGNING AUTHORITY 6 7. M

DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG CITIBANK, N.A., as Depositary, THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of June 18, 2021 TABLE OF CONTENTS

Exhibit 2.1 DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of June 18, 2021 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “Agent” 1 Section 1.4 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt

CERTIFICATION*

Exhibit 12.1 CERTIFICATION* I, Patrick Amstutz, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Partners AG (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misle

_____________________________________________________________________ LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG MOLECULAR PARTNERS AG

Exhibit 4.5 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG AND MOLECULAR PARTNERS AG 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION LICENSE AND COLLABORATION

CERTIFICATION*

Exhibit 12.2 CERTIFICATION* I, Robert Hendriks, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Partners AG (the "company"); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misle

Consent of Independent Registered Public Accounting Firm

Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement (No. 333-265960) on Form F-3 of Molecular Partners AG of our report dated March 8, 2023, with respect to the consolidated financial statements of Molecular Partners AG. /s/ KPMG Zurich, Switzerland March 8, 2023

MOLN / Molecular Partners AG / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Molecular Partners AG (Name of Issuer) Common Shares, CHF 0.10 nominal value per share (Title of Class of Securities) 60853G106 (CUSIP Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Molecular Partners Initiates Clinical Study of MP0533 for the Treatment of Acute Myeloid Leukemia (AML)

EXHIBIT 99.1 Molecular Partners Initiates Clinical Study of MP0533 for the Treatment of Acute Myeloid Leukemia (AML) · MP0533, a trispecific T cell engaging DARPin, targets CD33-CD123-CD70 with a unique avidity driven mechanism; engaging CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells · Preclinical data demonstrated that MP0533 can sel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

EXHIBIT 99.1 Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents Dose escalation remains ongoing with study recruitment anticipated to complete in 1H

Condensed consolidated interim financial statements (unaudited)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Z?rich-Schlieren Switzerland Telephone: +41 4475

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Z?rich-Schlieren Switzerland Telephone: +41 4475

Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-40488 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Wagistrasse 14 8952 Z?rich-Schlieren Switzerland Telephone: +41 4475

At a Glance: Key Milestones, Group Profile & Contents H1 2022 Research & Development Milestones MP0317 (FAP x CD40) ◦ Phase 1 open-label dose escalation study continues in patients with solid tumors known to express FAP. Initial clinical data from th

At a Glance: Key Milestones, Group Profile & Contents H1 2022 Research & Development Milestones MP0317 (FAP x CD40) ? Phase 1 open-label dose escalation study continues in patients with solid tumors known to express FAP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execut

Molecular Partners Reports Corporate Highlights and H1 2022 Financials

EXHIBIT 99.1 Molecular Partners Reports Corporate Highlights and H1 2022 Financials Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022 Initiation of Phase 1 study for MP0533 expected by year end Continued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers; next-generation T-cell engagers

HALF - YEAR REPORT 2022 In \ MOLECULAR partners Custom - bu il t biology for pat i ents 2 At a Glance: Key Milestones, Group Profile & Contents H1 2022 Research & Development Milestones MP0317 (FAP x CD40) ◦ Phase 1 open - label dose escalation study

EXHIBIT 99.2 HALF - YEAR REPORT 2022 In \ MOLECULAR partners Custom - bu il t biology for pat i ents 2 At a Glance: Key Milestones, Group Profile & Contents H1 2022 Research & Development Milestones MP0317 (FAP x CD40) ? Phase 1 open - label dose escalation study continues in patients with solid tumors known to express FAP . Initial clinical data from this study expected to be presented at a confe

[Signature page follows]

July 8, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius Re: Molecular Partners AG Registration Statement on Form F-3 Filed July 1, 2022 File No. 333-265960 Acceleration Request Requested Date: July 12, 2022 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 und

Form of Indenture between the Registrant and one or more trustees to be named

Exhibit 4.3 MOLECULAR PARTNERS AG Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Switzerland (State or other jurisdiction of incorporation or organization) Not Applicable (I.R.S. Employer Identification Number) Wagistrasse 14 8952 Z?rich-Schlieren Switzerland Telepho

Articles of association of the registrant

Exhibit 3.1 Statuten von Molecular Partners AG vom 13. April 2022 Articles of Incorporation of Molecular Partners Ltd as of April 13, 20221 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration of the Company

Filing Fee Exhibit.

EX-FILING FEES 2 molecularpartners-fx3july2.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Molecular Partners AG (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum

Sales Agreement

Exhibit 1.2 EXECUTION VERSION MOLECULAR PARTNERS AG SALES AGREEMENT July 1, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Molecular Partners AG, stock corporation (Aktiengesellschaft) organized under the laws of Switzerland (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Securities LLC (the ?Agent?), as follows: 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-40488

6-K 1 f6k061322.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (

5418 12 - June - 2022 SARS - CoV - 2 Omicron And Multi - variant Neutralization Activity Of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid - 19 Charles G. Knutson, Novartis Institutes for BioMedical Research, Cambridge, MA, USA Co -

Exhibit 99.1 5418 12 - June - 2022 SARS - CoV - 2 Omicron And Multi - variant Neutralization Activity Of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid - 19 Charles G. Knutson, Novartis Institutes for BioMedical Research, Cambridge, MA, USA Co - Authors: S. Rothenberger 1 , M. Walser 2 , F. Malvezzi 2 , D. L. Hurdiss 3 , J. Mayor 1 , H. Moreno 1 , S. Ryter 4 , N. Liechti 4 , A. B

Condensed consolidated interim financial statements (unaudited)

Exhibit 99.2 Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of March 31, 2022 December 31, 2021 in CHF thousands Note Assets Property, plant and equipment 7,949 8,146 Intangible assets 285 331 Total non-current assets 8,234 8,477 Short-term time deposits 154,229 61,000 Prepaid expenses and accrued income 3,886 5,728

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executive

Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum

EXHIBIT 99.1 Interim Management Statement Q1 2022 of Molecular Partners: Cash Runway into 2026 and Portfolio Progress Highlight Strategic Momentum ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 (GLOBE NEWSWIRE) - Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protei

Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call

EXHIBIT 99.1 Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) - Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, is pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

Molecular Partners to Regain Global Rights for MP0310 from Amgen Multi-specific DARPin targeting FAP x 4-1BB presently in Phase 1 clinical trial

EXHIBIT 99.1 Molecular Partners to Regain Global Rights for MP0310 from Amgen Multi-specific DARPin targeting FAP x 4-1BB presently in Phase 1 clinical trial ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 26, 2022 (GLOBE NEWSWIRE) - Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-4048

6-K 1 f6k042622.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting

EXHIBIT 99.1 Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 13, 2022 (GLOBE NEWSWIRE) - Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the shareholders

To the shareholders of Molecular Partners AG (Company) Invitation to the Annual General Meeting 2022 Wednesday, April 13 , 2022 , 2 : 00 p . m . Molecular Partners AG, 5 th Floor, Wagistrasse 14 , 8952 Schlieren , Switzerland Due to the ongoing COVID

EXHIBIT 99.2 To the shareholders of Molecular Partners AG (Company) Invitation to the Annual General Meeting 2022 Wednesday, April 13 , 2022 , 2 : 00 p . m . Molecular Partners AG, 5 th Floor, Wagistrasse 14 , 8952 Schlieren , Switzerland Due to the ongoing COVID pandemic, the Board of Directors has decided to conduct the annual general meeting 2022 in accordance with Article 8 of the Federal Act

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

Molecular Partners Publishes Invitation to Annual General Meeting 2022

EXHIBIT 99.1 Molecular Partners Publishes Invitation to Annual General Meeting 2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2022 (GLOBE NEWSWIRE) - Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2022.

Description of Securities

Exhibit 2.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of Molecular Partners AG (?Molecular Partners,? the ?Company,? ?we,? ?us,? and ?our?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the

Performance Share Plans 2022 - Management

Molecular Partners AG: Performance Share Plan 2022 ? Management Board Exhibit 4.14 Molecular Partners AG Performance Share Plan 2022 Management Board 1 Molecular Partners AG: Performance Share Plan 2022 ? Management Board Table of Contents Performance Share Plan 2022 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Gr

License Agreement, dated as of January 17, 2022, by and between Molecular Partners AG and Novartis Pharma AG.

Exhibit 4.5 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG AND MOLECULAR PARTNERS AG 264813180 v3 Table of Contents 1. DEFINITIONS AND INTERPRETATION 3 2. LICENSE 17 3. GOVERNANCE 20

Performance Share Plans 2022 - Employees

Molecular Partners AG: Performance Share Plan 2022 - Employees Exhibit 4.13 Molecular Partners AG Performance Share Plan 2022 Employees 1 Molecular Partners AG: Performance Share Plan 2022 - Employees Table of Contents Performance Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of PSUs 4 6. No S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-4048

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executi

Certification of Chief Financial Officer Pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934

Exhibit 12.2 CERTIFICATION* I, Andreas Emmenegger, certify that: 1. I have reviewed this annual report on Form 20-F of Molecular Partners AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re

Form of American Depositary Receipt (included in Exhibit 2.1).

Exhibit 2.1 DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of June 18, 2021 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 ?ADS Record Date? 1 Section 1.2 ?Affiliate? 1 Section 1.3 ?Agent? 1 Section 1.4 ?American Depositary Receipt(s)?, ?ADR(s)? and ?Receipt

Certification of Chief Executive Officer Pursuant to Rule 13(a)-14(a) of the Securities Exchange Act of 1934

Exhibit 12.1 CERTIFICATION* I,Patrick Amstutz, certify that: 1. I have reviewed this Annual Report on Form 20-F of Molecular Partners AG; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respec

Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021

EXHIBIT 99.1 Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021 Research & Development Highlights: In January of 2022, announced positive topline results from Phase 2 EMPATHY clinical trial of ensovibep for the treatment of non-hospitalized COVID-19 patients, resulting in the option exercise of the program by Novartis triggering the receipt of CHF 15

Restricted Share Plan 2022

Molecular Partners AG: Restricted Share Plan 2022 Exhibit 4.20 Molecular Partners AG Restricted Share Plan 2022 1 Molecular Partners AG: Restricted Share Plan 2022 Table of Contents Restricted Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of RSUs 4 6. No Securities 4 7. No Transfer 4 8. Vestin

License and Collaboration Agreement, dated as of December 13, 2021, by and between Molecular Partners AG and Novartis Pharma AG.

Exhibit 4.6 [ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG AND MOLECULAR PARTNERS AG 264814036 v4 EXECUTION COPY CONFIDENTIAL INFORMATION LICENSE AND COLLABORATION

Performance Share Plan 2021 - Management

Molecular Partners AG: Performance Share Plan 2021 ? Management Board Exhibit 4.12 Molecular Partners AG Performance Share Plan 2021 Management Board 1 Molecular Partners AG: Performance Share Plan 2021 ? Management Board Table of Contents Performance Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Gr

Organizational Rules of the registrant

Exhibit 1.2 ORGANIZATIONAL RULES OF MOLECULAR PARTNERS AG Approved by the Board of Directors October 6, 2014 (as amended as of May 12, 2017, September 20, 2017, February 5, 2019, April 29, 2020 and March 14, 2022) TABLE OF CONTENTS I. GENERAL PROVISIONS 3 1. BASIS 3 2. SCOPE 3 II. BOARD OF DIRECTORS 3 3. ORGANIZATION 3 4. FUNCTION AND POWERS 4 5. DUTIES 4 6. DELEGATION AND SIGNING AUTHORITY 6 7. M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13(a)-14(b) of the Securities Exchange Act of 1934

Exhibit 13.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the ?Exchange Act?) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. ?1350), Patrick Amstutz, Chief Executive Officer of Molecular Partners AG (the ?Company?), and Andreas Emmenegger, Chief Financial Officer of the Company, each here

Articles of Association, as currently in effect.

Exhibit 1.1 Statuten von Molecular Partners AG vom 20. Januar 2022 Articles of Incorporation of Molecular Partners Ltd as of January 20, 20221 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration of the Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19

EXHIBIT 99.1 Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) - Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein dr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19

EXHIBIT 99.1 Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19 Agreement grants global rights of ensovibep to Novartis, who will lead further development and commercialization of the program Financial terms include milestone payment of CHF150 million to Molecular Partners and 22% royalty on ensovibep sales in relevant territories Collaboration will focus on ra

MOLN / Molecular Partners AG / BIOTECHNOLOGY VALUE FUND L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Molecular Partners AG (Name of Issuer) Common Shares, CHF 0.10 nominal value per share (Title of Class of Securities) 60853G106 (CUSIP Num

MOLN / Molecular Partners AG / BIOTECHNOLOGY VALUE FUND L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Molecular Partners AG (Name of Issuer) Common Shares, CHF 0.10 nominal value per share (Title of Class of Securities) 60853G106 (CUSIP Num

Ensovibep Clinical Results Call 1 EMPATHY Part A January 2022 Mol ec ul ar Pa r t ne rs A G, S w itz er l and (SIX: MOLN, NASDAQ: MOLN) Ensovibep: 3 Advancement of COVID - 19 Clinical Program 4 Structure and Features of Ensovibep Neutralizing the SAR

EX-99.2 3 exh992.htm PRESENTATION Exhibit 99.2 Ensovibep Clinical Results Call 1 EMPATHY Part A January 2022 Mol ec ul ar Pa r t ne rs A G, S w itz er l and (SIX: MOLN, NASDAQ: MOLN) D i scla i mer 2 This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward - looking statements as that term is d

Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19 Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2022 Commission File Number: 001-40488 Molecular Par

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2022 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executive office) Indi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Custom Built Biology for Patients 1 Oncology Day 2021 Molecular P artners A G, S witzerland (SIX: MOLN) This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it o

Exhibit 99.1 Custom Built Biology for Patients 1 Oncology Day 2021 Molecular P artners A G, S witzerland (SIX: MOLN) This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology

EXHIBIT 99.1 Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis? in radioligand therapy to explore the potential for novel targeted therapies for cancer Novartis will pay $20 million upfront, commercial royalties u

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro

EXHIBIT 99.1 Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concern Testing on the full Omicron variant has initiated, with results expected in the coming weeks Global Phase 2-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19 Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized patients The global phase 2-3 EMPATH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal exec

Condensed consolidated interim financial statements (unaudited)

EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 Condensed consolidated interim financial statements (unaudited) Condensed consolidated interim statement of financial position as of September 30, 2021 December 31, 2020 in CHF thousands Note Assets Property, plant and equipment 8,448 9,387 Intangible assets 265 347 Total non-current assets 8,713 9,734 Short-term time deposits 71,348 40,000 Prepaid ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execu

Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum

EXHIBIT 99.1 Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) - Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 15, 2021 with respect to the Common Shares, CHF 0.10 nominal value per share of Molecular Partners AG, incorporated as an Aktiengesellschaft, or AG, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned purs

MOLN / Molecular Partners AG / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Molecular Partners AG (Name of Issuer) Common Shares, CHF 0.10 nominal value per share (Title of Class of Securities) 60853G106 (CUSIP Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execut

Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021 -- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPA

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021 - Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 Research & Development: Initiated two global Phase 2 and 3 trials of ensovibep (MP0420)

HALF - YEAR REPORT 2021 in \ MOLECULAR partners C u s t o m - b u i l t biolog y fo r p a t i en t s 2 A t a G l a n c e : K e y M i l e s t o n e s , G r o u p P r o f i l e & C o nt e nt s • A d v a n c e m e n t o f b a l a n c e d p o r t f o l i

EX-99.2 3 exh992.htm EXHIBIT 99.2 Exhibit 99.2 HALF - YEAR REPORT 2021 in \ MOLECULAR partners C u s t o m - b u i l t biolog y fo r p a t i en t s 2 A t a G l a n c e : K e y M i l e s t o n e s , G r o u p P r o f i l e & C o nt e nt s • A d v a n c e m e n t o f b a l a n c e d p o r t f o l i o o f d i ff e r e n t i a t e d D A R P i n ® p r o d u c t c a n d i d a t e s offering patients a n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-404

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal execut

Molecular Partners to Regain Global Rights to Abicipar

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Molecular Partners to Regain Global Rights to Abicipar Global rights to registrational-stage ophthalmology drug return to Molecular Partners Improvements in manufacturing and formulation have been made and tested in pre-clinical models with the potential to overcome inflammatory side effects Ongoing research discovery alliance with AbbVie in ophthalm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-40488

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-40488 Molecular Partners AG (Translation of registrant's name into English) Wagistrasse 14 8952 Zurich-Schlieren Switzerland (Address of principal executiv

Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2

EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrating Maintained Inhibition of Delta and All Other Known Variants of Concern of SARS-CoV-2 Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the D

3,000,000 American Depositary Shares Representing 3,000,000 Common Shares $21.25 per American Depositary Share

Filed pursuant to Rule 424(b)(4) Registration No. 333-255447 PROSPECTUS 3,000,000 American Depositary Shares Representing 3,000,000 Common Shares $21.25 per American Depositary Share This is the initial public offering of our American Depositary Shares, or ADSs. We are selling 3,000,000 common shares in the form of ADSs in the United States. Each ADS represents the right to receive one common shar

Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep

Filed Pursuant to Rule 433 under the Securities Act of 1933 Issuer Free Writing Prospectus dated June 14, 2021 Relating to Preliminary Prospectus issued June 10, 2021 Registration No.

As filed with the U.S. Securities and Exchange Commission on June 14, 2021.

As filed with the U.S. Securities and Exchange Commission on June 14, 2021. Registration No. 333-255447 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Switzerland 2836 Not applicable (State or other jurisdiction of

[Signature Page Follows]

Wagistrasse 14 8952 Z?rich-Schlieren Switzerland VIA EDGAR June 11, 2021 U.S Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Terence O'Brien Ms. Ada Sarmento Mr. Tim Buchmiller Re: Molecular Partners AG Registration Statement on Form F-1 File No. 333-255447 Acceleration Request Requested Date: June 15, 2021 Requ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Molecular Partners AG (Exact name of registrant as specified in its charter) Switzerland Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificatio

[Signature Page to Underwriters’ Acceleration Request]

J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 June 11, 2021 VIA EDGAR U.S Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Terence O'Brien Ms. Ada Sarmento

As filed with the U.S. Securities and Exchange Commission on June 10, 2021.

As filed with the U.S. Securities and Exchange Commission on June 10, 2021. Registration No. 333-255447 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Switzerland 2836 Not applicable (State or other jurisdiction of

Cooley LLP 500 Boylston Street 14th Floor Boston, MA 02116-3736 t: (617) 937-2300 f: (617) 937-2400 cooley.com

Ryan Sansom + 1 617 937 2335 [email protected] Via EDGAR June 10, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Terence O?Brien Ms. Ada Sarmento Mr. Tim Buchmiller Re: Molecular Partners AG Amendment No. 3 to Registration Statement on Form F-1 Filed on June 9, 2021 File No. 333-255447 Ladies and G

Form of Underwriting Agreement.

EX-1.1 2 exhibit11-formofunderwriti.htm EX-1.1 Exhibit 1.1 MOLECULAR PARTNERS AG [●] American Depositary Shares, representing [●] Common Shares Underwriting Agreement , 2021 J.P. Morgan Securities LLC SVB Leerink LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Le

DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG CITIBANK, N.A., as Depositary, THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [l], 2021 TABLE OF CONTENTS

Exhibit (a) DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [l], 2021 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 ?ADS Record Date? 1 Section 1.2 ?Affiliate? 1 Section 1.3 ?Agent? 1 Section 1.4 ?American Depositary Receipt(s)?, ?ADR(s)? and ?Receipt(s)?

Form of American Depositary Receipt (included in Exhibit 4.1).

Exhibit 4.1 Execution Version DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [], 2021 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “Agent” 1 Section 1.4 “American Depositary Receipt(s)”, “ADR(s)”

Exhibit (d)

EX-99.(D) 3 e620565ex99-d.htm Exhibit (d) June 9, 2021 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose o

As filed with the U.S. Securities and Exchange Commission on June 9, 2021.

As filed with the U.S. Securities and Exchange Commission on June 9, 2021. Registration No. 333-255447 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Switzerland 2836 Not applicable (State or other jurisdiction of

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS MOLECULAR PARTNERS AG (Exact name of issuer of deposited sec

As filed with the Securities and Exchange Commission on June 9, 2021 Registration No.

As filed with the U.S. Securities and Exchange Commission on May 12, 2021.

As filed with the U.S. Securities and Exchange Commission on May 12, 2021. Registration No. 333-255447 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Switzerland 2836 Not applicable (State or other jurisdiction of

Cooley LLP 500 Boylston Street 14th Floor Boston, MA 02116-3736 t: (617) 937-2300 f: (617) 937-2400 cooley.com

Ryan Sansom + 1 617 937 2335 [email protected] Via EDGAR May 12, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Terence O?Brien Ms. Ada Sarmento Mr. Tim Buchmiller Re: Molecular Partners AG Registration Statement on Form F-1 Filed on April 22, 2021 File No. 333-255447 Ladies and Gentlemen: On behal

- F-1/A

As filed with the U.S. Securities and Exchange Commission on May 4, 2021. Registration No. 333-255447 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO.1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Switzerland 2836 Not applicable (State or other jurisdiction of in

Articles of Association, as currently in effect

Exhibit 3.1 Statuten von Molecular Partners AG vom 21. April 2021 Articles of Incorporation of Molecular Partners Ltd as of April 21, 20211 1 This is a translation of the original German version. In case of any discrepancy, the German version shall prevail. - 2 - Abschnitt 1: Firma, Sitz, Zweck und Dauer der Gesellschaft Section 1: Name, Place of Incorporation, Purpose and Duration of the Company

Amended and Restated Collaboration Agreement, dated as of August 17, 2012, by and among the University of Zurich, Molecular Partners AG, Allergan, Inc., and Allergan Sales, LLC

Exhibit 10.3 *** = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ***, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT This License and Collaboration Agreement (the “Agreement”) is entered into as of May 3, 2011 (the “Effective Date”) by and between (a) Molec

Collaboration and License Agreement, dated as of December 18, 2018, by and between Molecular Partners AG and Amgen Inc.

Exhibit 10.5 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT by and between MOLECULAR PARTNERS AG and AMGEN INC. December 18, 2018 TABLE OF CONTENT PAGE ARTICLE 1 DEFINITIONS 1 ARTICLE 2 COLLABORAT

2017 Performance Share Plan

Exhibit 10.7 Molecular Partners AG: Performance Share Plan 2017 Molecular Partners AG Performance Share Plan 2017 Molecular Partners AG: Performance Share Plan 2017 2 | 10 Table of Contents Performance Share Plan 2017 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of PSUs 4 6. No Securities 5 7. No Transfer 5

2018 Performance Share Plan

Exhibit 10.8 Molecular Partners AG: Performance Share Plan 2018 Molecular Partners AG Performance Share Plan 2018 Molecular Partners AG: Performance Share Plan 2018 2 | 12 Table of Contents Performance Share Plan 2018 3 1. Purpose 3 2. Definitions and Interpretation 3 3, Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of PSUs 4 6. No Securities 5 7. No Transfer 5

2020 Restricted Share Plan

EX-10.16 19 exhibit1016-fx1.htm EX-10.16 Exhibit 10.16 Molecular Partners AG: Restricted Share Plan 2020 Molecular Partners AG Restricted Share Plan 2020 Molecular Partners AG: Restricted Share Plan 2020 2 | 9 Table of Contents Restricted Share Plan 2020 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 4 4. Eligibility and Participation 4 5. Grant of RSUs 4

Subsidiaries of the Registrant

EX-21.1 21 exhibit211-fx1.htm EX-21.1 Exhibit 21.1 Principal Subsidiaries of the registrant Name of subsidiary Country of incorporation Molecular Partners Inc. United States of America

2017 Restricted Share Plan

EX-10.13 16 exhibit1013-fx1.htm EX-10.13 Exhibit 10.13 Molecular Partners AG: Restricted Share Plan 2017 Molecular Partners AG Restricted Share Plan 2017 Annex 4RSU Plan 2017for CC Approval Molecular Partners AG: Restricted Share Plan 2017 2 | 9 Contents Restricted Share Plan 2017 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Partici

Power of Attorney of each of the directors of the registrant and the principal executive, financial and accounting officers of the registrant (included on signature page)

As filed with the U.S. Securities and Exchange Commission on April 22, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter) Switzerland 2836 Not applicable (State or other jurisdiction of incorporation or organi

Cooley LLP 500 Boylston Street 14th Floor Boston, MA 02116-3736 t: (617) 937-2300 f: (617) 937-2400 cooley.com

Ryan Sansom + 1 617 937 2335 [email protected] Via EDGAR April 22, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christie Wong Mr. Terence O?Brien Ms. Ada Sarmento Mr. Tim Buchmiller Re: Molecular Partners AG Draft Registration Statement on Form F-1 Submitted on March 15, 2021 CIK No. 0001745114 Ladies and Gentleme

2020 Performance Share Plan

Molecular Partners AG: Performance Share Plan 2020 Exhibit 10.10 Molecular Partners AG Performance Share Plan 2020 Molecular Partners AG: Performance Share Plan 2020 2 | 10 Table of Contents Performance Share Plan 2020 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of PSUs 4 6. No Securities 5 7. No Transfer 5

License Agreement, dated as of November 17, 2004, as amended, by and between The University of Zurich and Molecular Partners AG

Exhibit 10.2 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT This agreement (?Agreement?) is made by and between The University of Zurich Ramistrasse 71 CH-8006 Zurich (Switzerland) (?UNIVERSITY?) And Molecular Part

2021 Performance Share Plan for Management

Exhibit 10.12 Molecular Partners AG: Performance Share Plan 2021 – Management Board Molecular Partners AG Performance Share Plan 2021 Management Board Molecular Partners AG: Performance Share Plan 2021 – Management Board 2 | 2 Table of Contents Performance Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4

2018 Restricted Share Plan

Exhibit 10.14 Molecular Partners AG: Restricted Share Plan 2018 Molecular Partners AG Restricted Share Plan 2018 Molecular Partners AG: Restricted Share Plan 2018 2 | 9 Table of Contents Restricted Share Plan 2018 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of RSUs 4 6. No Securities 4 7. No Transfer 5 8. V

Discovery Alliance Agreement, dated as of August 12, 2012, as amended, by and among Molecular Partners AG, Allergan, Inc, and Allergan Sales, LLC

Exhibit 10.4 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DISCOVERY ALLIANCE AGREEMENT This Discovery Alliance Agreement (the “Agreement”) is entered into as of August 20, 2012 (the “Effective Date”) by and between (a) Molecular P

Option and Equity Rights Agreement, dated as of October 27, 2020, by and between Molecular Partners AG and Novartis Pharma AG

EX-10.6 9 exhibit106-fx1.htm EX-10.6 Exhibit 10.6 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Option and Equity Rights Agreement by and between Novartis Pharma AG and Molecular Partners AG, dated 27 October, 2020 1. DEFINITIONS A

2019 Performance Share Plan

EX-10.9 12 exhbit109-fx1.htm EX-10.9 Molecular Partners AG: Performance Share Plan 2019 Exhibit 10.9 Molecular Partners AG Performance Share Plan 2019 Molecular Partners AG: Performance Share Plan 2019 2 | 10 Table of Contents Performance Share Plan 2018 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of PSUs 4

Form of indemnification agreement between the registrant and each of its executive officers and directors

EX-10.1 4 exhibit101-fx1.htm EX-10.1 Exhibit 10.1 Draft | April 17, 2021 Indemnification Agreement dated as of [month] [day], [year] by and between Molecular Partners AG (the Company) Wagistrasse 14 8952 Schlieren Switzerland [e-mail] and [Name of Director / Executive] (the Indemnitee and, together with the Company, the Parties and each, a Party) [address] [e-mail] regarding the indemnification of

2021 Restricted Share Plan

Exhibit 10.17 Molecular Partners AG: Restricted Share Plan 2021 Molecular Partners AG Restricted Share Plan 2021 Molecular Partners AG: Restricted Share Plan 2021 2 | 9 Table of Contents Restricted Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 4 5. Grant of RSUs 4 6. No Securities 4 7. No Transfer 5 8. V

Organizational Rules of the registrant (English translation)

Exhibit 3.2 ORGANIZATIONAL RULES OF MOLECULAR PARTNERS AG Approved by the Board of Directors October 6, 2014 (as amended as of May 12, 2017, September 20, 2017, February 5, 2019 and April 29, 2020) Table of Contents I. GENERAL PROVISIONS 3 1. BASIS 3 2. SCOPE 3 II. BOARD OF DIRECTORS 3 3. ORGANIZATION 3 4. FUNCTION AND POWERS 4 5. DUTIES 4 6. DELEGATION AND SIGNING AUTHORITY 6 7. MEETINGS 6 8. AGE

2019 Restricted Share Plan

EX-10.15 18 exhibit1015-fx1.htm EX-10.15 Exhibit 10.15 Molecular Partners AG: Restricted Share Plan 2019 Molecular Partners AG Restricted Share Plan 2019 Molecular Partners AG: Restricted Share Plan 2019 2 9 Table of Contents Restricted Share Plan 2019 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of RSUs 4 6

2021 Performance Share Plan for Employees other than Management

Exhibit 10.11 Molecular Partners AG: Performance Share Plan 2021 - Employees Molecular Partners AG Performance Share Plan 2021 Employees Molecular Partners AG: Performance Share Plan 2021 - Employees 2 | 12 Table of Contents Performance Share Plan 2021 3 1. Purpose 3 2. Definitions and Interpretation 3 3. Responsibilities and Administration 3 4. Eligibility and Participation 3 5. Grant of PSUs 4 6

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 MOLECULAR PARTNERS AG (Exact name of registrant as specified in its charter)

As confidentially submitted to the U.S. Securities and Exchange Commission on March 12, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURI